Congress cuts tariffs on breast cancer survivor medical devices
H.R. 10147 — To amend the Harmonized Tariff Schedule for the United States to establish a new subheading in chapter 39 for silicone prosthetics for women who are breast cancer survivors and a new subheading in chapter 90 for mastectomy bras. · Filed by Carol Miller (R-WV) · 1 cosponsor · Introduced Aug 24, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill eliminates tariffs on silicone breast prosthetics and mastectomy bras by creating two new tariff categories effective January 1, 2027. Breast cancer survivors and others using these medical devices will pay no import duty (0%), while foreign competitors face a 25–90% tariff, making these devices cheaper for U.S. consumers and manufacturers.
Why we flagged it
The bill's sole operative mechanism is the elimination of import duties on two specific medical devices used by breast cancer survivors. It is a straightforward tariff amendment with no secondary provisions or riders.
What the text implies
- Domestic manufacturers of these devices may face increased competition from lower-cost imports, potentially affecting U.S. production and employment in this niche medical-device sector.
- The tariff elimination applies to imports from most developed and developing nations (listed in the 'Special' column), but the 25–90% general tariff remains for non-listed countries, creating a two-tier import regime.
The full analysis lists 3 implications of this text.
Who stands to gain
breast cancer survivors and patients (lower device costs); foreign manufacturers and importers of silicone prosthetics and mastectomy bras; U.S. retailers and distributors of these devices (lower wholesale costs)